Exagen to Announce Third Quarter Financial Results on November 10, 2020
October 27 2020 - 4:05PM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, today announced that it will release financial
results for the quarter ended September 30, 2020 after the market
close on Tuesday, November 10, 2020. Ron Rocca, President and Chief
Executive Officer, and Kamal Adawi, Chief Financial Officer, will
host a conference call to review the Company’s results at 4:30 PM
Eastern Time (1:30 PM Pacific Time).
Interested parties may access the conference call by dialing
(877) 407-3982 (U.S.) or (201) 493-6780 (international).
Participants wishing to access the call via webcast should use the
link posted on the Exagen investor relations website at
https://investors.exagen.com/.
A replay of the conference call will be available until Tuesday,
November 17, 2020 at 11:59 PM Eastern Time (8:59 PM Pacific Time).
Interested parties may access the replay of the conference call by
dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international)
using passcode 13711892. Additionally, a recording of the webcast
will be available using the link on the Exagen investor relations
website approximately 30 minutes after the call concludes.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis.
CONTACTS:
Investors
Westwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838
Company Contact
Exagen Inc.Kamal Adawi, Chief Financial
OfficerKAdawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024